The mean CDR-SB score at baseline was approximately 3.2 in both groups. 2 key findings →
Design: clinical trial Participants: 1,795 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
30,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
The findings suggest that risk factors associated with ADRDs have changed over the past decade and differ based on sex and race and ethnicity. 5 key findings →
Design: meta-analysis Participants: 378 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Despite older racial and ethnic minorities (REMs) being more likely to develop dementia they are underrepresented in clinical trials focused on neurological disorders. 5 key findings →
Design: systematic review Participants: 100,748 Evidence: high
Full summary, score breakdown and related studies → Original source
Our systematic review indicates that a majority of studies examining the vision-cognition relationship report that VI is associated with more cognitive decline, cognitive impairment or dementia among older adults. 4 key findings →
Design: systematic review Participants: 100 Evidence: high
Full summary, score breakdown and related studies → Original source
79/100
Patients with AD spectrum demonstrated altered GM abundance, which was differentially mediated by countries and clinical stages. 5 key findings →
Design: systematic review Participants: 427 Evidence: high
Full summary, score breakdown and related studies → Original source
The present study will address several shortcomings of previous CCT studies. 5 key findings →
Design: randomized controlled trial Participants: 162 Evidence: high
Full summary, score breakdown and related studies → Original source
Identifying ancestry-specific molecular profiles of late-onset Alzheimer's Disease (LOAD) in brain tissue is crucial to understand novel mechanisms and develop effective interventions in non-European, high-risk populations. 3 key findings →
Design: meta-analysis Participants: 731 Evidence: high
Full summary, score breakdown and related studies → Original source
We screened 18,884 papers and included 135 studies. 5 key findings →
Design: meta-analysis Participants: 135 Evidence: high
Full summary, score breakdown and related studies → Original source
The muscarinic receptor agonist xanomeline improved cognition in phase 2 trials in Alzheimer's disease and schizophrenia. 3 key findings →
Design: clinical trial Participants: 60 Evidence: high
Full summary, score breakdown and related studies → Original source
Fosgonimeton and placebo were shown to be safe and well-tolerated across all doses. 5 key findings →
Participants: 48 Evidence: high
Full summary, score breakdown and related studies → Original source
Compared with placebo, the amino acid mixture did not improve NPI-12, MMSE, TMT-A and B or CDR scores. 4 key findings →
Participants: 36 Evidence: high
Full summary, score breakdown and related studies → Original source
CSF Aβ42, t-tau, p-tau, tau/Aβ42; peripheral blood t-tau, Aβ42/Aβ40, NFL; whole, left and right HV, EC volume, MTA, 18 F-FDG PET, 11 C-PIB PET; APOE ε4 may be promising prospective biomarkers for AD progression. 3 key findings →
Design: meta-analysis Participants: 70 Evidence: high
Full summary, score breakdown and related studies → Original source
Dropout rates were 5.1% for atomoxetine and 2.7% for placebo, with no significant differences in adverse events. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
In both amyloid-positive cohorts (ADNI [age = 75.99±7.69] and A05 [age = 74.03±9.03]), cognitive-domain-specific tau-PET outperformed global and temporal-lobe tau-PET for predicting future cognitive decline in episodic memory, language, executive functioning, and visuospatial abilities. 3 key findings →
Design: meta-analysis Participants: 121 Evidence: high
Full summary, score breakdown and related studies → Original source
The Clinical Dementia Rating Scale-Sum of Boxes was selected as the primary outcome measure, in which post-treatment scores were compared to baseline. 5 key findings →
Design: clinical trial Evidence: high
Full summary, score breakdown and related studies → Original source
Non-invasive Gamma ENtrainment Using Sensory stimulation (GENUS) at 40Hz reduces Alzheimer's disease (AD) pathology such as amyloid and tau levels, prevents cerebral atrophy, and improves behavioral testing performance in mouse models of AD. 4 key findings →
Design: clinical trial Participants: 25 Evidence: high
Full summary, score breakdown and related studies → Original source
PA was associated with lower incidence of all-cause dementia and Alzheimer's disease, even in longer follow-ups, supporting PA as a modifiable protective lifestyle factor, even after reducing the effects of reverse causation. 5 key findings →
Design: meta-analysis Participants: 257,983 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In participants with prodromal to mild AD in this randomized clinical trial, semorinemab did not slow clinical AD progression compared with placebo throughout the 73-week study period but did demonstrate an acceptable and well-tolerated safety profile. 3 key findings →
Design: clinical trial Participants: 422 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The variability in disease onset was compared with that of autosomal dominant Alzheimer disease. 5 key findings →
Design: meta-analysis Participants: 77 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
78/100
Of 19 114 randomized participants, 16 855 (88.2%) had longitudinal gait and cognitive data for inclusion in this study (mean [SD] age, 75.0 [4.4] years; 9435 women [56.0%], 7558 participants [44.8%] with 12 or more years of education). 5 key findings →
Design: cohort study Participants: 7,558 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Pain is inversely associated with cognitive function in older adults, but the effects of pain on cognitive decline are not fully clear. 1 key finding →
Design: randomized controlled trial Participants: 688 Evidence: high
Full summary, score breakdown and related studies → Original source
Fifty-two studies (20 randomised; 32 non-randomised) with 4786 participants diagnosed with cancer (n = 4491), dementia (n = 43), AIDS (n = 235), spasticity (n = 16), NORSE syndrome (n = 1) were included. 1 key finding →
Design: meta-analysis Participants: 4,491 Evidence: high
Full summary, score breakdown and related studies → Original source
Well-designed and executed RCTs are needed to confirm our findings on stroke and to have more scientific evidence available for the other neurological diseases. 4 key findings →
Participants: 2,335 Evidence: high
Full summary, score breakdown and related studies → Original source
Both t-tau and p-tau are suitable AD blood biomarkers, and p-tau217 is more sensitive than other tau biomarkers to differentiate MCI and AD. 3 key findings →
Design: systematic review Participants: 56 Evidence: high
Full summary, score breakdown and related studies → Original source
Multidomain lifestyle modification is considered an effective intervention for dementia prevention due to its multifactorial nature. 2 key findings →
Design: randomized controlled trial Participants: 40 Evidence: high
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,180 records, built mostly from automated pulls of Europe PMC (64.2% of the library) and OpenAlex (16.9%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →